The term off-label use describes the prescription and administration of medicines outside of the terms for which it officially has been approved, including age, dose and indication. Off-label data can be generated from the Danish National Prescription Registry through combinations with diagnoses; however, the community pharmacy servers provide equal, local, albeit less data through a faster and less constrained collection process. The data collection for this exploratory study took place at five community pharmacies in Denmark. Five drugs were chosen for the investigation and collection of prescription data across a 2-year period. Off-label use by age was observed to be 1.9% for diclofenac, 1.7% for desmopressin and 2.3% for quetiapine. The percentages were based on total number of 3881, 925, 2712 prescriptions, respectively. Off-label monitored by dosage appeared to be 75% for quetiapine; by box label text analysis, off-label indication was found to be 10-15% and 15-23% for quetiapine and mirtazapine (from a total number of 3178 prescriptions), respectively. By route of administration where fucidin ointment was applied to the nose in 60 patients, 83% were prescribed off-label (non-dermatological). This exploratory study revealed that pharmacy servers represent a reliable and up-to-date source to collect a substantial amount of raw prescription data. The method gives straightforward and simple access to analysis of off-label use by age and dose, whereas it is possible but difficult to interpret off-label indications and route of administration from the box label text.
According to European Medicines Agency (EMA), the Summary of Product Characteristics or the 'label' is an official document approved as part of the marketing authorization, updated throughout the life cycle of the product if new data emerges [1] . Off-label use represents a difficult and complex issue to handle for physicians, the pharmaceutical industry and the regulatory authorities due to lack of current monitoring and sparse data for its prevalence [2] . In general, off-label medicines can be described as medicines that are used outside the terms of their marketing authorization regarding indication, dosing, route of administration or group of patients [3] . As off-label prescription represents an additional risk for patients, especially if it has widespread use, it is important for the health authorities to discover risky off-label behaviour in due time [3] . New routes and methods to gather information about off-label use should be considered in this process. Furthermore, this method may be of equal interest to pharmaceutical companies as they are required to monitor potential off-label use of their products as part of an approved risk management plan. Data for identification of off-label use can be found in national prescription registries. The same data, albeit only for household records, also exist within community pharmacy servers. The latter source was the basis for the present investigation for off-label prescriptions for selected medicines in Denmark.
Background
The demonstration of a positive benefit-risk ratio is a prerequisite for obtaining authorization by EMA/national agencies for pharmaceutical companies to access the market for their medicines. When a new medicine is released, the benefit-risk ratio based on randomized trials conducted before release will change due to the wider prescription. At first, physicians follow the authorized treatment recommendations (the label), possibly supplemented by guidance from scientific societies and governmental bodies [4] . Incentives for physicians for off-label treatment can also be obtained from scientific publications, or they could be communicated through colleagues via their professional network [5] . In case a patient does not respond to current pharmacotherapy, it appeals to the general practitioner (GP) to try 'something different' for his/her illness and may thus lead to off-label prescribing [6] . However, if the aim of the treatment is to gain systematic, additional knowledge about the mechanism of action of the medicine, it is considered human experimentation which requires permission from the health authorities [7] .
Studies of off-label prescribing in common medical practice (primary care) show that this phenomenon is not limited to a single country, a special group of doctors or even linked to a specific condition [8] . In Denmark, the Danish National Prescription Registry contains data on all prescription medicine sold in community pharmacies which is used for medical product transactions of purchase and reimbursement and collecting statistics for health authorities [9] . Via the civil registration number (in Danish: CPR) which is given to all citizens in Denmark, links can be established to other registries, for example the patient registry. Thus, in a straightforward pharmacoepidemiology study for identifying off-label use, the linkage of registries of patient diagnoses and drug prescription is performed giving the full picture of off-label practice in Denmark [9] . However, even for research purposes, there are restrictions regarding access and payment. Another drawback is the fact that only established diagnoses from hospitals will appear in the patient registry. Primary care, except for specific diseases, for example diabetes, does not have a registry for their diagnoses [10] . The text on the package label, or rather the sticker that the pharmacist puts on the container of the medicine (including name of the patient, the active pharmaceutical ingredient (API) name, dose regimen, indication (diagnose) or symptom to be treated), does not appear in the registry. Instead, the indication is presented as a code (e.g. the indication code for depression is 168). However, full original prescription data can be found in Danish community pharmacy servers. Depending on the server's capacity, data are collected for a period of minimum 2 years according to Danish law [11] . It contains both indication code and the package label information, which comprises of indication as a text. Instead of choosing the indication from a drop-down menu (linked to the indication code), some prescribers prefer free-text wording. 'Soft diagnoses' based on common symptoms like insomnia and headache will appear which then could be linked to both correct and off-label use. This information does not appear in the Danish National Prescription Registry (DNPR), but it is valuable for research as it may contain the off-label indications. This has been carried out, for example, for off-label of antipsychotic medicines [12] .
Analysing box label text for off-label use has been carried out by free-text mining [13] , but to our knowledge not through a systematic direct reading of the prescriber's free wording on the label for specific medicines. Thus, the prescriber's description of the indication and instruction for the patient given in the box label text could be a source for identifying and thereby monitoring off-label medications.
The aim of this exploratory study was to collect and analyse the four types of off-label use, that is indication, dosing, route of administration and intended patient population from prescription data stored in servers of five representative community pharmacies in Denmark.
Materials and Methods
Prescription data over 2 years of five different medicines suspected for off-label use were collected from five Danish pharmacies in May and June 2017. Only prescriptions dispensed to a patient the first time were counted. When no information of the indication was found in the box label text, the prescriptions were excluded as non-eligible.
According to Danish Medicines Agency in 2017, Denmark had 237 pharmacies [14] each serving an average of 23,000 customers. Thus, the five selected pharmacies cover approximately 2% of the total Danish population. They deliver data from two regions (of five) including both the capital, capital suburbs, town and rural area. The A, B and E pharmacies are located in the outer city area, whereas C belongs to inner city and D to suburbs. B represents a rural area. The factor expressing the variation between different pharmacies is calculated as the difference between the highest and lowest off-label percentage value in relation to the average.
Five different medicines were chosen for this study after investigation and discussion with physicians, both GPs and specialists, pharmacists and university colleagues for possible off-label use. Diclofenac belongs to a non-steroidal anti-inflammatory (NSAID) group of drugs. Even though newer NSAIDs are authorized for paediatric use [15] , we expected that this well-established drug is still used off-label for children. In the Danish authorization, desmopressin is to be used only for patients below 65 years unless dose adjustment is performed. This may happen even with the existence of a new medicine, Noctura â , specifically authorized by EMA for use in the elderly. Quetiapine and mirtazapine are only approved by authorities for severe conditions like bipolar disease and depression. However, abandoning of benzodiazepines in Denmark for chronic sleeping disorders has created room for exploiting the off-label sedative effects of these antipsychotics as sleeping medicines. In search for off-label prescriptions by route of administration, the antibiotic ointment fucidin was chosen. It has indication only for dermal application but is expected (when applied for the nose) to be used for mucosa as well.
The CITO software (Birkerød, Denmark) is used daily by personnel of pharmacies as a 'housekeeper' to record the delivered medicines and print the prescription labels. It is installed in about 20% of all Danish community pharmacies of significance for this project. It stores prescription data in the specific pharmacy server for two or more years [11] and further sends the data directly to the Danish National Prescription Registry, which is regulated by Statistics Denmark. As a further advantage, it is possible to construct a search function (code) for the stored data via special-purpose programming language -Standard Query Language (SQL).
Standard Query Language code for withdrawing the prescription information was programmed by CITO IT. Extracted data contain name and surname of the patient, CPR number, physician's code (encrypted), prescription date, product and indication code (in Denmark, all medical products and authorized indications have their own code), trade name of the drug, ATC code and prescription text for the box label (name and surname, text for dose regimen and indication and API). In order to use the SQL code appropriately, two actual conditions have to be changed from the original code: the time frame starting 2 years back from the present day (collection day) and ATC code.
All prescription data were collected in April and May 2017. The data consisted of 2-year prescriptions counting back from the actual day of collection. The data included all prevalent uses of the active ingredient, both on-going and new, but prescriptions were only counted once. The primary analysis was carried out in the pharmacy to prevent the sensitive data, for example personal identification number and the name of the patient from leaving the pharmacy. The interpretation for categorization of the package text was at the author's discretion. Age of the patient was calculated before the personal information was deleted from the prescription data. Prescriptions were processed in Microsoft Office program Excel using functions, filters or manual analysis.
The Danish data protection law is strict, but it is possible to obtain permission for data collection in the pharmacies as long as the analysis of the data takes place inside the pharmacy so that only non-identifiable consolidated data leave the pharmacy premises. The project was approved by The Danish Data Protection Agency. Individual agreements were signed for all involved investigators who had direct access to the raw data (SUND-2017-19).
Results
The obtained data are disposed according to the four categories of off-label practice, and the results of relevant medicines are presented under these headings.
Off-label use by age. Table 1 gives numbers for diclofenac off-label use as monitored by age. Diclofenac is not approved to treat patients below 18 years [16] . The analysis shows that 74 prescriptions were dispensed for patients younger than 18 years, which on average is 1.9% of off-label use of diclofenac [17] . It is representative as the range of distribution of off-label prescriptions between the pharmacies only varied with a factor 1.8.
In case of desmopressin, 925 prescriptions were found in the five pharmacies of the study (table 2) . Desmopressin is authorized only for patients below 65 years [18] . It is specifically not recommended to be used for patients above 65 years, unless the daily dosage is adjusted to 25 lg for women and 50 lg for men [18] . Off-label use for desmopressin for this category of patients was 95%. The range of distribution for off-label prescriptions varied between the pharmacies only with a factor 1.2.
Quetiapine, mirtazapine and diclofenac are authorized to be used only for patients above 18 years. The number of off-label prescriptions found for children (<18 years) corresponded to 145 out of 7518 examined, which represents 2%. Of those 145 prescriptions, 50 (35%) were prescribed for patients below 14 years (table 3) .
Off-label use by dosage. Low doses of desmopressin are authorized for patients above 65 years; however, only nine of 168 prescriptions for elderly patients included the correct dosage (table 2) .
A total number of 2712 quetiapine prescription were collected (table 4). As quetiapine comes in tablets of 25, 50, 100, 150, 200, 300 and 400 mg, the dose regimen was stratified in two groups: >100 and ≤100 mg. As the lowest effective daily dosage for quetiapine is 150 mg, a daily dosage of 100 mg or less may identify off-label use [19] . This daily dosage is prescribed most frequently corresponding to 75% of the off-label prescriptions. The finding that tablets containing 25 mg of quetiapine are the most prescribed size supports this. The off-label practice was equally distributed among the pharmacies, and they differed only by a factor 1.2.
Off-label by indication. The authorized indications by Danish Medicines Agency for quetiapine are schizophrenia, bipolar disorder and depression [20] . In Denmark, physicians can choose between six recommended indications for their box label text: psychosis, bipolar disorder, depression, mania, CNS medicines and mental illness [21] . However, the collected prescription data of the box label text showed much more variation in the indications. To help in the analysis, they were categorized into three major groups: authorized indications, likely off-label indications and most likely off-label indications. The likely off-label prescription contains indications expressed as symptoms that may be linked to psychosis diagnosis. Table 5 shows examples of the key words for indication groups which were chosen by the doctors when prescribing quetiapine and mirtazapine. Sleep disturbances and anxiety were the most used indications. Some very specific and single indications were also included in the category of 'most likely off-label' but are not stated in the table.
Of 2712 quetiapine prescriptions, 85% are categorized as authorized, 5% as likely off-label and 10% as most likely to represent off-label indications (table 6) . Thus, off-label usecounted in this manner for the five pharmacies -appears to be in the range of 10-15%. Similar grouping was performed for mirtazapine. The off-label use of mirtazapine was in the range of 15-23% which is similar to quetiapine. An additional offlabel indication, headache, was found for mirtazapine (1.2%) and was categorized as off-label. The range of distribution between the pharmacies differed by a factor 2 and 1.2 for quetiapine and mirtazapine, respectively.
Further, the discrepancy found between box label text and dose prompted a closer look for correlation between prescribed dose and authorized indication (table 7). Table 7 depicts that high dose in a prescription most likely indicates the use of correct indication.
Off-label use by route of administration.
Fucidin ointment is used for various dermal infections. However, it is not authorized for mucosa, that is inside the nose. In total, 8221 of fucidin prescriptions were dispensed in the 2-year period in the five pharmacies [22] . Indication for the nose (60 prescriptions in total) was again categorized to authorized, likely off-label (i.e. having an unclear text for the application site) and most likely off-label giving rise to 6, 6 and 48 prescriptions, respectively. Comparing to the total number of fucidin prescriptions, the off-label use is on average 0.58%, but for the nose alone, it is 80%.
Discussion
To our knowledge, it is the first time that a large number of box labels for medicines suspected for off-label practice have been manually investigated and interpreted. Otherwise, Jung et al. performed a study with a data-mining approach, where a predictive model was used to find off-label prescriptions. Data were collected from two databases (Medi-Span and DrugBank) where free-text clinical notes were studied [23] . Wong et al. [12] investigated off-label use of antidepressants by studying indication based on electronic prescriptions with the main objective to study the occurrence of off-label indications by class and by the individual drug.
In principle, the box label text should indicate that the prescribed medicines are used off-label [11] . Even small changes in the condition for which the drug is authorized to be applied for can be considered as off-label practice [5] . For example, in case of quetiapine and mirtazapine, symptoms like 'unrest' or 'bad thoughts' can be used on the box label instead of the authorized indications which are bipolar disease or schizophrenia. This gives access to better information on the actual intentions for use (in contrast to the 'naked' diagnose code noted in the DNPR). On the other hand, it opens up the possibility of observer bias.
For intended off-label use, some physicians, due to ethical reasons, avoid putting the 'grim' diagnosis like schizophrenia on the exposed box label. Quetiapine and mirtazapine are good examples as they expose around 15% off-label use by indication. (table 6 ) Instead of writing non-authorized indication or symptom(s), the GPs are making up new phrases, using neutral/non-pathological wording, for example by avoiding prefixes like hypo-, hyper-in diagnosis or symptom text, or describing unusual disease symptoms. They also may apply generalized terms as drug category or employ purely descriptive medical terms. However, a few mirtazapine prescriptions were for posttraumatic stress disorder and obsessive-compulsive disorder. These indications could be explained due to treatment recommended by relevant medical societies [24]. The implementation of electronic prescribing may lead to or might already have led to the use of standardized (authorized) indications due to its appearance as a drop-down menu, even though the actual use is off-label [12] . In Denmark, it is possible to type in the indication code corresponding to the indication for all medicines.
One of the reasons that off-label practice is generally accepted is that it allows for the identification of useful treatment indications for existing authorized medicines [5] . Thus, new indications are applied for quetiapine and mirtazapine, for example all types of sleeping problems and anxiety and more specifically for the latter, treatment of pain conditions like headaches (table 5) . The expansion of the treated population with quetiapine through inclusion of the large population of patients with sleeping disorders, estimated by extrapolation of our results to be about 90,000 (table 4) for the whole country, could have a negative impact, as it may present a higher risk of adverse drug reactions (ADR) as compared to authorized sleeping medicine.
In agreement with Kamphuis et al. [20] , we also found that quetiapine was prescribed for the non-authorized indication insomnia. Hereby, quetiapine reaches a much larger population than it might have been anticipated in the original authorization, subsequently influencing the original benefit-risk analysis. GPs might think that use of low quetiapine daily dosages does not pose a risk. However, we have not found any literature demonstrating that the individual susceptibility for sudden death due to QT interval prolongations should disappear at the lowest daily dosage [25] . Our data reveal that 75% of all prescriptions for quetiapine were lower or equal to 100 mg daily, which is again in agreement with the Kamphuis et al. [20] findings. Comparing daily dosage and indication showed that 86% of prescriptions contained the authorized indication (table 7) . Daily dose by different generic manufacturers of quetiapine varies for different conditions; however, lowest recommended daily dosage is above 100 mg/day in all cases. Therefore, this could be a reasonable indicator of off-label use, as physicians could be 'cheating' the monitoring system by prescribing lower doses which are ineffective for authorized indications. Unfortunately, the same analysis cannot be conducted for mirtazapine, as the therapeutic dose and the dose used for sleeping disorders are in a close range.
Generally speaking, the medicines authorized before 2007 were at first only authorized for patients over 18 years.
Though, for quetiapine, mirtazapine and diclofenac, the offlabel use for children equals 2% (145 prescriptions out of 7518). The ADR profile may be the same as in adults, but it has not been examined for children [17] .
Interestingly, more than half (65%) of the three examined medicines, that is diclofenac, quetiapine and mirtazapine prescribed for children were dispensed for patients between 14 and 18 years (table 3) . This shows that inclusion criteria in the original clinical trial are neglected by the GPs, as such sharp age boundaries do not make sense as the physiology changes gradually and individually by age. The same pattern was found in a study of antidepressants [26] .
Summary of Product Characteristics often contains sparse data on elderly patients (>65 years) [27] . It is different for desmopressin [18] ; however, 95% of the identified prescriptions for patients above 65 years were found to be off-label. Such use imposes additional risk of hypokalaemia which needs continuous monitoring while taking the medicine [28] .
Off-label practice by route of administration is the most complicated issue to study. In case of fucidin (with 83% of off-label use for nose application), the GPs may think that the use of ointment which functions on skin also will be effective on mucosa. Here, toxicity is not a risk as it can be given orally [29] .
The pharmacy setting represents a window to study the real world of medicine consumers [30] that has not yet been fully exploited. As shown in this study, it is possible in the pharmacy setting, via their servers, to obtain information on realworld data, namely off-label use of medicines suspected to be prescribed as such. Further, it has been utilized to perform interviews with patients who experience ADRs of the prescribed medicine [30, 31] . In a similar way, information on the effectiveness of a new pharmacotherapy can be obtained by asking the patient to fill in a questionnaire either when the treatment is initiated or upon the shift to new medication. These questions are repeated when the next batch of medicines must be picked up whereby information of the treatment effect can be monitored [32] .
In conclusion, online data collection from local pharmacy servers in Denmark using SQL code was found to be easy, fast and free of costs. Reliable off-label data on age can be easily obtained whereas box label text analysis is valuable but ambiguous. The procedure of dispensing at the pharmacy represents an underexploited source for searching data for supplementary information of the behaviour of patients and doctors in the real world. 
